Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

NCT02049541 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma
Waldenström Macroglobulinemia

Interventions

DRUG: PI3K inhibitor BKM120
BIOLOGICAL: rituximab
OTHER: Pharmacodynamics
OTHER: Correlative studies

Sponsor

Kami Maddocks, MD

Collaborators

[object Object]